Literature DB >> 15972969

Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate.

Beatrice S Knudsen1, Jared M Lucas, Ladan Fazli, Sarah Hawley, Seth Falcon, Ilsa M Coleman, Dan B Martin, Chang Xu, Lawrence D True, Martin E Gleave, Peter S Nelson, Gustavo E Ayala.   

Abstract

Hepatocyte activator inhibitor-1 (HAI-1) is a transmembrane serine protease inhibitor that regulates the conversion of latent to active hepatocyte growth factor (HGF). Studies supporting a role for the HGF pathway in prostate carcinogenesis prompted an analysis of HAI-1 expression in the prostate. Here we analyze the regulation of HAI-1 expression by androgen, oncogenic transformation, and cancer progression. Immunohistochemical analysis revealed that HAI-1 expression was restricted to prostate epithelium, where staining occurred primarily in basal and atrophic luminal epithelial cells. Compared to normal glands, HAI-1 expression was significantly increased in localized prostate cancer and was present in most prostate cancer metastases. HAI-1 protein expression levels were sensitive to androgen in normal epithelium but not in cancer. Although androgen did not increase HAI-1 protein expression levels in LNCaP cells, it decreased HAI-1 surface expression, consistent with previous data from our group (Martin DB, Gifford DR, Wright ME, Keller A, Yi E, Goodlett DR, Aebersold R, Nelson PS: Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res 2004, 64:347-355). HAI-1 overexpression in cancer was predictive of prostate-specific antigen recurrence (relative risk, 1.24). These results suggest that HAI-1 regulates the HGF Met axis on prostate epithelial cells and influences HGF mediated tumor invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15972969      PMCID: PMC1603455          DOI: 10.1016/S0002-9440(10)62970-7

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  48 in total

1.  Significance analysis of microarrays applied to the ionizing radiation response.

Authors:  V G Tusher; R Tibshirani; G Chu
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

2.  Characterization of prostate cell types by CD cell surface molecules.

Authors:  Alvin Y Liu; Lawrence D True
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

3.  Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion.

Authors:  Geert van Leenders; Bianca van Balken; Tilly Aalders; Christina Hulsbergen-van de Kaa; Dirk Ruiter; Jack Schalken
Journal:  Prostate       Date:  2002-05-01       Impact factor: 4.104

4.  The program of androgen-responsive genes in neoplastic prostate epithelium.

Authors:  Peter S Nelson; Nigel Clegg; Hugh Arnold; Camari Ferguson; Michael Bonham; James White; Leroy Hood; Biaoyang Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-16       Impact factor: 11.205

5.  Inadequate formalin fixation decreases reliability of p27 immunohistochemical staining: probing optimal fixation time using high-density tissue microarrays.

Authors:  Angelo M De Marzo; Helen H Fedor; Wesely R Gage; Mark A Rubin
Journal:  Hum Pathol       Date:  2002-07       Impact factor: 3.466

Review 6.  Pericellular activation of hepatocyte growth factor/scatter factor (HGF/SF) in colorectal carcinomas: roles of HGF activator (HGFA) and HGFA inhibitor type 1 (HAI-1).

Authors:  H Kataoka; H Itoh; R Hamasuna; J Y Meng; M Koono
Journal:  Hum Cell       Date:  2001-03       Impact factor: 4.174

7.  Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis.

Authors:  Karin List; Christian C Haudenschild; Roman Szabo; WanJun Chen; Sharon M Wahl; William Swaim; Lars H Engelholm; Niels Behrendt; Thomas H Bugge
Journal:  Oncogene       Date:  2002-05-23       Impact factor: 9.867

8.  Delineation of prognostic biomarkers in prostate cancer.

Authors:  S M Dhanasekaran; T R Barrette; D Ghosh; R Shah; S Varambally; K Kurachi; K J Pienta; M A Rubin; A M Chinnaiyan
Journal:  Nature       Date:  2001-08-23       Impact factor: 49.962

9.  Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.

Authors:  Michael D Oberst; Michael D Johnson; Robert B Dickson; Chen-Yong Lin; Baljit Singh; Moira Stewart; Alastair Williams; Awatif al-Nafussi; John F Smyth; Hani Gabra; Grant C Sellar
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

10.  Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells.

Authors:  C Parr; W G Jiang
Journal:  Int J Oncol       Date:  2001-10       Impact factor: 5.650

View more
  4 in total

1.  Expression of ERG protein in prostate cancer: variability and biological correlates.

Authors:  Gustavo Ayala; Anna Frolov; Deyali Chatterjee; Dandan He; Susan Hilsenbeck; Michael Ittmann
Journal:  Endocr Relat Cancer       Date:  2015-06       Impact factor: 5.678

2.  Expression of hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma and postoperative outcomes.

Authors:  Mayumi Funagayama; Kazuhiro Kondo; Kazuo Chijiiwa; Hiroaki Kataoka
Journal:  World J Surg       Date:  2010-07       Impact factor: 3.352

Review 3.  Inflammation in prostate carcinogenesis.

Authors:  Angelo M De Marzo; Elizabeth A Platz; Siobhan Sutcliffe; Jianfeng Xu; Henrik Grönberg; Charles G Drake; Yasutomo Nakai; William B Isaacs; William G Nelson
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

4.  Roles of Kunitz domains in the anti-invasive effect of hepatocyte growth factor activator inhibitor type 1 in human glioblastoma cells.

Authors:  Shiro Miyata; Tsuyoshi Fukushima; Kazuyo Kohama; Hiroyuki Tanaka; Hideo Takeshima; Hiroaki Kataoka
Journal:  Hum Cell       Date:  2007-11       Impact factor: 4.174

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.